Advertisement
Document › Details
CureVac AG. (11/21/18). "Press Release: CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference". Tübingen & Boston, MA.
Region | New York, NY | |
Country | United States (USA) | |
Organisation | CureVac AG | |
Today | CureVac SE | |
Group | CureVac (Group) | |
Organisation 2 | Piper Jaffray & Co. (NYSE: PJC) | |
Today | Piper Sandler Companies (NYSE: PIPR) | |
Group | Piper Sandler (Group) | |
Product | Piper Jaffray Annual Healthcare Conference 2018 New York | |
Product 2 | mRNA technology | |
Index term | CureVac–Piper Jaffray: investor conference, 201811 supply service CureVac presents at Piper Jaffray Healthcare Conference 2018 | |
Person | Menichella, Daniel L. (Dan) (Kaleido Biosciences 202010– CEO before CureVac + Bamboo Therapeutics + AGTC + Zyngenia) | |
Person 2 | Beck, Matthew L. S. (Matt) (Hookipa 202210 Investor Relations before CureVac + Solebury Trout) | |
CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan Menichella, Chief Executive Officer, will present a corporate overview at the 19th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2018 at 10:50 a.m. ET.
A live audio broadcast of the presentation will be available at www.curevac.com/en/newsroom/curevacevents. An archived replay of the presentation will be available on the company’s website for 3 months following the presentation.
About CureVac AG
CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.
To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s dievini and an investment of $52 million from the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation.
For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.
***
Investor Contact
Matthew Beck, Vice President Investor Relations
CureVac AG, Boston, MA, United States
T: +1 917-415-1750
matthew.beck@curevac.com
Record changed: 2023-06-05 |
Advertisement
More documents for CureVac (Group)
- [1] CureVac N.V.. (1/17/24). "Press Release: CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock". Tübingen & Boston, MA....
- [2] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
- [3] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....
- [4] CureVac N.V.. (9/28/23). "Press Release: CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany". Tübingen & Boston, MA....
- [5] CureVac N.V.. (8/17/23). "Press Release: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update". Tübingen & Boston, MA....
- [6] LimmaTech Biologics AG. (7/20/23). "Press Release: LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth". Schlieren....
- [7] CureVac N.V.. (7/14/23). "Press Release: CureVac Announces Update to the Management Team". Tübingen & Boston, MA....
- [8] CureVac N.V.. (5/19/23). "Press Release: CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech". Tübingen....
- [9] CureVac N.V.. (2/8/23). "Press Release: CureVac Announces Pricing of Upsized Public Offering of Common Shares". Tübingen & Boston, MA....
- [10] CureVac N.V.. (2/6/23). "Press Release: CureVac Announces Proposed Public Offering of Common Shares". Tübingen & Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top